# A Trial Evaluating the Safety & Efficacy of Intra-Tumoral Ipilimumab in Combination With Intra-venous Nivolumab in Patients With Metastatic Melanoma

> **NCT02857569** · PHASE1,PHASE2 · COMPLETED · sponsor: **Gustave Roussy, Cancer Campus, Grand Paris** · enrollment: 90 (actual)

## Conditions studied

- Stage III/IV Melanoma

## Interventions

- **DRUG:** Ipilimumab IT
- **DRUG:** Ipilimumab IV
- **DRUG:** Nivolumab IV

## Key facts

- **NCT ID:** NCT02857569
- **Lead sponsor:** Gustave Roussy, Cancer Campus, Grand Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-05
- **Primary completion:** 2021-01
- **Final completion:** 2022-05-20
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2023-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02857569

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02857569, "A Trial Evaluating the Safety & Efficacy of Intra-Tumoral Ipilimumab in Combination With Intra-venous Nivolumab in Patients With Metastatic Melanoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02857569. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*